Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Kevin R. Flaherty et al.|The Lancet Respiratory Medicine|2020Cited by 558
Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised PatientsLuca Richeldi, Leonardo M. Fabbri, Angela Ferrari et al.|CHEST Journal|2009Cited by 157